mRNA Platform Evolution: Expanding from Vaccines to Therapeutics

The messenger RNA (mRNA) platform has proven its significance with COVID-19 vaccines and is now facing its second major test. Building on the success of COVID-19 vaccines, the platform is expanding into new areas, including seasonal flu, respiratory syncytial virus (RSV) infections, and treatments for cancer and rare diseases. The evolution of the mRNA platform is seen as a pivotal moment for the bio industry as it seeks new growth drivers in the post-COVID era.

According to a report by global market research firm Vision Research Report, the global mRNA vaccine and therapeutic market is expected to grow from $10.66 billion in 2024 to $45.04 billion by 2034, reflecting an annual growth rate of 15.5%. Within this, the mRNA cancer vaccine market is projected to nearly double, increasing from $8.1 billion to $15.7 billion during the same period.

This growth indicates that mRNA technology is creating new markets by extending beyond preventive vaccines into therapeutic areas. An industry insider noted, "While there were predictions that the mRNA vaccine market might experience a temporary slowdown after the COVID-19 pandemic, it is expected to maintain its growth trajectory through the expansion of new indications such as flu, RSV, and cancer vaccines."

The expansion of mRNA into new areas is driven by the structural limitations of traditional egg-based cultivation methods. Typically, it takes 5 to 6 months to produce a single vaccine using egg cultivation, during which time the virus may mutate, reducing the vaccine's effectiveness. In contrast, mRNA can be designed within weeks once the genetic information of the pathogen is obtained, providing a significant advantage in responding to mutations.

Leveraging these advantages, the mRNA platform is moving beyond preventive vaccines into therapeutic applications. Recent developments in personalized cancer vaccines and treatments for rare diseases are rapidly broadening its medical applications.

There is growing optimism in the market that the era of designing personalized cancer vaccines based on patients' genetic information is becoming a reality. U.S. companies Moderna and Merck (MSD) have reported significant treatment effects in a Phase 3 clinical trial for melanoma patients using their cancer vaccine "Intusmeran Autogen" in combination with the immunotherapy "Keytruda," compared to Keytruda alone. This marks the first time mRNA-based therapies have demonstrated efficacy in the oncology field, extending beyond infectious diseases like COVID-19.

Global pharmaceutical and biotech companies are expanding the application of cancer vaccines to more prevalent cancers, such as lung, bladder, and pancreatic cancers, suggesting a shift in the paradigm of cancer drug development.

Jung Yoon-taek, head of the Pharmaceutical Industry Strategy Research Institute, stated, "The combination of mRNA and lipid nanoparticles (LNP) is expected to expand the platform's applicability not only to infectious diseases but also to various types of cancer. It is encouraging that the South Korean government has allocated 40.5 billion won for mRNA-related budgets. This indicates that national-level investments to proactively respond to future infectious diseases will become more active."